Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OneSource Specialty PharmaNSE:ONESOURCE -2.14%8 EV-to-EBITDA is 53.83 as of Aug. 26, 2026, which is 5% above its 10-year median of 51.25. GuruFocus rates NSE:ONESOURCE with a GF Score™ of 8/100. The stock has 3 warning signs investors should review. Among 413 Biotechnology companies, OneSource Specialty Pharma ranks worse than 82.57% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, OneSource Specialty Pharma's enterprise value is ₹183,715 Mil.
OneSource Specialty Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹3,413 Mil. Therefore, OneSource Specialty Pharma's EV-to-EBITDA for today is 53.83.
The historical rank and industry rank for OneSource Specialty Pharma's EV-to-EBITDA or its related term are showing as below:
NSE:ONESOURCE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 32.11 Med: 51.25 Max: 106.55
Current: 53.83
During the past 4 years, the highest EV-to-EBITDA of OneSource Specialty Pharma was 106.55. The lowest was 32.11. And the median was 51.25.
NSE:ONESOURCE's EV-to-EBITDA is ranked worse than 82.57% of 413
companies
in the Biotechnology industry
Industry Median: 13.87
vs NSE:ONESOURCE: 53.83
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
OneSource Specialty Pharma's PE Ratio (TTM) for today is calculated as:
OneSource Specialty Pharma's share price for today is ₹1483.60.
OneSource Specialty Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-4.250.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ONESOURCE vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, OneSource Specialty Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OneSource Specialty Pharma EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OneSource Specialty Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where OneSource Specialty Pharma's EV-to-EBITDA falls into.
OneSource Specialty Pharma's current Enterprise Value is ₹183,715 Mil.
OneSource Specialty Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3,413 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OneSource Specialty Pharma (NSE:ONESOURCE) has a EV-to-EBITDA of 53.83 as of Aug. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on OneSource Specialty Pharma. This is near median its historical median of 51.25. Over the past decade, OneSource Specialty Pharma's EV-to-EBITDA has ranged from 32.11 to 106.55. According to the industry distribution chart, OneSource Specialty Pharma ranks #341 out of 413 companies in the Biotechnology industry, placing it in the top 82.6%.
Is OneSource Specialty Pharma's EV-to-EBITDA too high?
OneSource Specialty Pharma's current EV-to-EBITDA of 53.83 is near median its 10-year median of 51.25. Over the past 10 years, this metric has ranged from a low of 32.11 to a high of 106.55. The Biotechnology industry median EV-to-EBITDA is 13.87. OneSource Specialty Pharma's value of 53.83 is 288.1% above this industry median. Based on the distribution chart, OneSource Specialty Pharma ranks #341 out of 413 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OneSource Specialty Pharma has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does OneSource Specialty Pharma's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OneSource Specialty Pharma ranks #341 out of 413 companies for EV-to-EBITDA. This places OneSource Specialty Pharma in the lower half of its industry. The industry median EV-to-EBITDA is 13.87. OneSource Specialty Pharma's value of 53.83 is 288.1% above this benchmark. Historically, OneSource Specialty Pharma's own EV-to-EBITDA has ranged from 32.11 to 106.55 over the past decade. While the company's 10-year median is 51.25 vs. the industry median of 13.87, OneSource Specialty Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.87, based on 413 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OneSource Specialty Pharma's current EV-to-EBITDA of 53.83 is 288.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on OneSource Specialty Pharma. For the Biotechnology industry, the median EV-to-EBITDA is 13.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OneSource Specialty Pharma's current EV-to-EBITDA is 53.83, which is near median its own 10-year median of 51.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OneSource Specialty Pharma stock overvalued right now?
OneSource Specialty Pharma (NSE:ONESOURCE) has a current EV-to-EBITDA of 53.83. The current EV-to-EBITDA is 53.83, which is near median its 10-year median of 51.25 and 288.1% above the Biotechnology industry median of 13.87. OneSource Specialty Pharma's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For OneSource Specialty Pharma (NSE:ONESOURCE), the current EV-to-EBITDA is 53.83 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OneSource Specialty Pharma Ltd is engaged in the research, development, manufacture and commercialization of biological drug products in different injectable formats. The company also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. The company's reportable segments are CDMO (Contract Development and Manufacturing Organization (CDMO) : Development and manufacture of pharmaceutical products and associated services); and Unit-3 Multimodal Facility and CDMO-2.
8GF Score
Get the complete analysis for NSE:ONESOURCE
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ONESOURCE has been successfully added to your 
